ATE554787T1 - Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern - Google Patents

Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern

Info

Publication number
ATE554787T1
ATE554787T1 AT07025199T AT07025199T ATE554787T1 AT E554787 T1 ATE554787 T1 AT E554787T1 AT 07025199 T AT07025199 T AT 07025199T AT 07025199 T AT07025199 T AT 07025199T AT E554787 T1 ATE554787 T1 AT E554787T1
Authority
AT
Austria
Prior art keywords
prediposition
markers
expression
type
treatment
Prior art date
Application number
AT07025199T
Other languages
English (en)
Inventor
Habib Zaghouani
Randal Keith Gregg
Original Assignee
Univ Missouri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Missouri filed Critical Univ Missouri
Application granted granted Critical
Publication of ATE554787T1 publication Critical patent/ATE554787T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07025199T 2002-04-09 2003-04-08 Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern ATE554787T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37166302P 2002-04-09 2002-04-09

Publications (1)

Publication Number Publication Date
ATE554787T1 true ATE554787T1 (de) 2012-05-15

Family

ID=29250718

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07025199T ATE554787T1 (de) 2002-04-09 2003-04-08 Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern
AT03723930T ATE382367T1 (de) 2002-04-09 2003-04-08 Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03723930T ATE382367T1 (de) 2002-04-09 2003-04-08 Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern

Country Status (6)

Country Link
EP (2) EP1938834B1 (de)
AT (2) ATE554787T1 (de)
AU (2) AU2003230830A1 (de)
DE (1) DE60318423T2 (de)
ES (1) ES2301794T3 (de)
WO (2) WO2003086286A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132686A1 (en) * 2009-05-13 2010-11-18 Gliknik, Inc. Methods of using immunoglobulin aggregates
DK3214942T3 (da) 2014-11-07 2021-05-25 Dupont Nutrition Biosci Aps Rekombinant værtscelle, der udtrykker beta-galactosidase- og/eller transgalactosyleringsaktivitet, der er deficient i mannanase, cellulase og pektinase
EP3383891A1 (de) 2015-12-04 2018-10-10 Novartis AG Antikörpercytokingepfropfte zusammensetzungen und verfahren zur verwendung zur immunoregulierung
EP3607097B1 (de) 2017-04-07 2023-06-21 DuPont Nutrition Biosciences ApS Bacillus-wirtszellen, welche beta-galactosidasen und lactasen in abwesenheit von p-nitrobenzylesterase nebenaktivität produzieren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103967A1 (en) 1997-01-07 2003-06-05 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CA2310269A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Immunoglobulin molecules having a synthetic variable region and modified specificity
WO1999032136A1 (en) * 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Chimeric proteins for the treatment of diabetes
JP2004509978A (ja) 2000-06-05 2004-04-02 ユニバーシティ　オブ　テネシー　コーポレイション 免疫抑制因子のエンドサイトーシスによる提示のための組成物及び方法
AU2002307062A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
CN108533209B (zh) 2018-04-02 2020-07-10 中国石油天然气股份有限公司 固井水泥的体积稳定性的确定装置和方法

Also Published As

Publication number Publication date
AU2003223528A1 (en) 2003-10-27
EP1938834A1 (de) 2008-07-02
EP1499346A2 (de) 2005-01-26
WO2003086296A3 (en) 2004-02-26
EP1499346B1 (de) 2008-01-02
ATE382367T1 (de) 2008-01-15
AU2003230830A8 (en) 2003-10-27
DE60318423D1 (de) 2008-02-14
AU2003230830A1 (en) 2003-10-27
WO2003086296A2 (en) 2003-10-23
WO2003086286A3 (en) 2004-04-22
WO2003086286A2 (en) 2003-10-23
DE60318423T2 (de) 2009-02-12
ES2301794T3 (es) 2008-07-01
EP1499346A4 (de) 2005-12-07
EP1938834B1 (de) 2012-04-25
AU2003223528A8 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
DE60117043D1 (de) Behandlung von mukositis
ATE427762T1 (de) Vorlage zur behandlung von hamorrhoiden
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
EA200001175A1 (ru) Бензотиофены, бензофураны и индолы, полезные в лечении устойчивости к инсулину и гипергликемии
ATE304849T1 (de) Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE335501T1 (de) Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen
ATE554787T1 (de) Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE142875T1 (de) Methode zur behandlung von haarausfall
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
DE60123528D1 (de) Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
SE7708176L (sv) Bensamidforeningar
EP1435962A4 (de) Behandlung von diabetes vom typ 1
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE318594T1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE60017786D1 (de) Zusammensetzung mit retinal und aldehyde mit pilzverhütender aktivität